Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Jul
14
Today In Oncology
Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors
Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy
Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC
Radiotherapy Dose Escalation With Intraoperative Radiotherapy vs Surgery Alone in Glioblastoma
Stage III HER2-Negative Breast Cancer With HRD Standard Chemotherapy Plus Olaparib
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo